GlassScriptPhysician profile
Amanda J Frazier
NPI 1235523879
$1,667.21
in general payments reported to CMS, 2019-2025
26 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $299 · 2022: $282 · 2023: $547 · 2024: $252 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $556.51 | 2021-2025 | |
| Novo Nordisk INC | $159.14 | 2021-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $136.97 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Idorsia Pharmaceuticals US INC | $122.89 | 2023 | Quviviq |
| Pfizer INC. | $83.26 | 2021-2025 | |
| Exact Sciences Corporation | $76.46 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.46 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $48.91 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.26 | 2021-2022 | |
| Lilly USA, LLC | $39.56 | 2021 | |
| Abbott Laboratories | $38.20 | 2022-2023 | Freestyle Libre 2 |
| Amgen INC. | $32.95 | 2021-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $31.74 | 2021-2024 | Gardasil 9, Gardasil, Vaxelis |
| Novartis Pharmaceuticals Corporation | $29.78 | 2021-2022 | |
| Shield Therapeutics INC | $29.58 | 2023-2025 | Accrufer |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $22.66 | 2025 | Auvelity |
| Eisai INC. | $21.87 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.55 | 2025 | |
| Inspire Medical Systems, INC. | $18.43 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $17.09 | 2024 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $14.48 | 2021 | |
| Amarin Pharma, INC. | $14.40 | 2021 | |
| Currax Pharmaceuticals LLC | $13.76 | 2023 | Contrave, Nexletol, Nexlizet |
| Vbi Vaccine (Delaware) INC. | $13.20 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.18 | 2021 | |
| Astellas Pharma US INC | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Frazier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.